A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RETaltered NSCLC and other tumors

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2024
This article has no abstract
Epistemonikos ID: ccaeec204902f44e4b72a7c295285b8304e02dfd
First added on: Feb 18, 2025